Table 4.

Occurrence of the AE hypertension and dose modifications because of (all) AEs.

	Grade 3–4	Dose Reduction	Interruption	Discontinuation
Selpercatinib [25]	21%	31%	5%	2%
Pralsetinib [26]	17%	NA	NA	4%
Cabozantinib [28]	8.4%	79%	65%	16%
Vandetanib [30]	9%	35%	NA	12%

NA—not available.